Coenzyme Q10 levels correlate with the activities of complexes I and II/III in mitochondria from Parkinsonian and nonparkinsonian subjects

Annals of Neurology

Volumn 42, Issue 2, 1997, Pages 261-264

  Shults, Clifford W ^a,b,d   Haas, Richard H ^b   Passov, David ^c   Beal, M Flint ^c  

^a VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); SUCCINATE DEHYDROGENASE (UBIQUINONE); UBIDECARENONE; UBIQUINOL CYTOCHROME C REDUCTASE; DRUG DERIVATIVE; MULTIENZYME COMPLEX; OXIDOREDUCTASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); SUCCINATE DEHYDROGENASE; UBIQUINONE;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ELECTRON TRANSPORT; ENZYME ACTIVITY; FEMALE; HUMAN; MALE; MITOCHONDRION; PARKINSON DISEASE; PRIORITY JOURNAL; BLOOD; ENZYMOLOGY; METABOLISM; REFERENCE VALUE; THROMBOCYTE;

BLOOD PLATELETS; ELECTRON TRANSPORT COMPLEX II; ELECTRON TRANSPORT COMPLEX III; FEMALE; HUMANS; MALE; MITOCHONDRIA; MULTIENZYME COMPLEXES; NAD(P)H DEHYDROGENASE (QUINONE); OXIDOREDUCTASES; PARKINSON DISEASE; REFERENCE VALUES; SUCCINATE DEHYDROGENASE; UBIQUINONE;

EID: 0030612117     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.410420221     Document Type: Article

References (16)

1. Langston JW, Ballard P, Tetrud JW, Irwin I. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983;219:979-980
2. Sayre LM. Biochemical mechanism of action of the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Toxicol Lett 1989;48:121-149
3. 1 reductase (complex I) deficiency in Parkinson's disease. J Neurochem 1990;55:2142-2145
4. Janetzky B, Hauck S, Youdim MBH, et al. Unaltered aconitase activity, but decreased complex I activity in substantia nigra pars compacta of patients with Parkinson's disease. Neurosci Lett 1994;169:126-128
5. Parker WD Jr, Boyson SJ, Parks JK. Abnormalities of the electron transport chain in idiopathic Parkinson's disease. Ann Neurol 1989;26:719-723
6. Yoshino H, Nakagawa-Hattori Y, Kondo T, Mizuno Y. Mitochondrial complex I and II activities of lymphocytes and platelets in Parkinson's disease. J Neural Transm 1992;4:27-34
7. Krige D, Carroll MT, Cooper JM, et al. Platelet mitochondrial function in Parkinson's disease. Ann Neurol 1992;32:782-788
8. Benecke R, Strümper P, Weiss H. Electron transfer complexes I and IV of platelets are abnormal in Parkinson's disease but normal in Parkinson-plus syndromes. Brain 1993;116:1451-1463
9. Haas R, Nasirian F, Nakano K, et al. Low platelet mitochondrial complex I and complex II/III activity in early untreated Parkinson's disease. Ann Neurol 1995;37:714-722
10. Ernster L, Dallner G. Biochemical, physiological and medical aspects of ubiquinone function. Biochim Biophys Acta 1995; 1271:195-204
11. Halliwell B, Gutteridge JMC. Oxygen radicals and the nervous system. Trends Neurosci 1985;8:22-26
12. Matsubara T, Azuma T, Yoshida S, Yamagami T. Serum coenzyme Q-10 level in Parkinson syndrome. In: Folkers K, Littarru GP, Yamagami T, eds. Biomedical and clinical aspects of coenzyme Q. Amsterdam: Elsevier Science, 1991:159-166
13. Gotz ME, Gerstner A, Janetsky B, et al. Platelet coenzyme Q10 in Parkinson's disease. Mov Disord 1996;11(suppl 1):127
14. Folkers K, Langsjoen P, Willis R, et al. Lovastatin decreased coenzyme Q levels in humans. Proc Natl Acad Sci USA 1990; 87:8931-8934
15. Fahn S, Cohen G. The oxidant stress hypothesis in Parkinson's disease: evidence supporting it. Ann Neurol 1992;32:804-812
16. Ikejiri Y, Mori E, Ishii K, et al. Idebenone improves cerebral mitochondrial oxidative metabolism in a patient with MELAS. Neurology 1996;47:583-585